<DOC>
	<DOCNO>NCT02134262</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy blood kinetics autologous T cell genetically modify express anti-CD19 Chimeric Antigen Receptor patient relapse refractory B-Cell Non-Hodgkin Lymphoma .</brief_summary>
	<brief_title>Gene Therapy B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes</brief_title>
	<detailed_description>Peripheral blood ( 600 mL ) collect subject obtain write informed consent complete 1st registration . Peripheral blood mononuclear cell ( PBMCs ) plasma obtain blood , T cell contain PBMCs transduce anti-CD19 CAR gene use SFG-1928z retroviral vector . Anti-CD19 CAR express T cell ( CD19-CAR-T ) expand use medium contain autologous plasma . After T cell pass quality control test , subject go 2nd registration . Subjects hospitalize administered Cyclophosphamide Day -2 Bendamustine Day -3 Day -2 intravenously Pre-treatment , subject receive 1st infusion CD19-CAR-T Day 0 Day 1 ( Day 1：1/3 dose , Day 2：2/3 dose ) split dose . In case sufficient cell number CD19-CAR-T manufacture , DLT observe CD19-CAR-T infusion , certain clinical effect observe additional treatment preferable , necessity 2nd infusion assess . In case 2nd infusion necessary , allow infuse appropriate timing . This study conduct base 3+3 dose escalation scheme . Three subject enrol group Dose Level . If one 3 subject show DLT DLT assessment period , another 3 subject add ; therefore , decision whether next Dose Level follow make base result obtain total 6 subject . The investigator assess tumor shrinkage effect CD19-CAR-T accordance `` Revised response criterion malignant lymphoma '' , 12 week 1st infusion CD19-CAR-T ( time termination ) . The investigator also assess safety follow-up period . Long-term follow-up study conduct frequency year 15 year 1st infusion CD19-CAR-T reference guideline FDA .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Relapsed refractory BNHL . 2 . Evaluable region identify CT scan positive FDGPET . 3 . 20 ≤ age ≤ 70 year time inform consent . 4 . ECOG performance status 02 . 5 . Well preserved main organ function . 6 . Life expectancy ≥3 month inform consent . 7 . Written informed consent . 1 . Other active malignancy . 2 . CNS infiltration lymphoma . 3 . History allogeneic stem cell transplantation . 4 . Already participated clinical trial CD19CART administer within 24 week . 5 . Concurrent use systemic steroid immunosuppressive agent . 6 . Concurrent severe heart disease . 7 . History severe cerebrovascular disease sequela include paralysis . 8 . Known active severe infection . 9 . HIV seropositive status . 10 . HBsAgpositive HBcAb HBVDNA positive . 11 . Active hepatitis C. 12 . Psychiatric disorder drug addiction affect ability inform consent . 13 . Pregnant breastfeed woman , woman may pregnant woman desire become pregnant . Men desire impregnate woman also exclude ( exclude : case sperm cryopreserved prior gene therapy child bear use sperm ) . 14 . Any patient judge investigator inappropriate subject study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Anti-CD19 CAR Expressing T cell Therapy</keyword>
	<keyword>CD19 CAR Gene-Transduced Lymphocyte</keyword>
	<keyword>Adoptive Immunotherapy</keyword>
	<keyword>Genetically Engineered Lymphocyte Therapy</keyword>
	<keyword>Retroviral Vector</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Follicular</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphomatoid Granulomatosis</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Large-Cell , Immunoblastic</keyword>
	<keyword>Lymphoma , B-Cell , Marginal Zone</keyword>
	<keyword>Lymphoma , Extranodal NK-T-Cell</keyword>
	<keyword>Lymphoma , Mantle-Cell</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms , Experimental</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>